UCB and Neuropore Enter Into World-Wide Collaboration and Agreement


(January 16, 2015) – UCB and Neuropore Therapies Inc. announced today that they have entered into a world-wide collaboration and agreement to develop and commercialize therapeutic products aiming at slowing the progression of Parkinson’s disease and related disorders. This includes NPT200-11, Neuropore’s novel small molecule that targets pathogenic alpha-synuclein which is currently in preclinical development and is expected to enter clinical Phase 1 in 2015.ad Read more...

Click for a printer friendly version

Back to top